Provided by Tiger Fintech (Singapore) Pte. Ltd.

Standard BioTools Inc.

1.06
+0.06616.65%
Post-market: 1.070.0100+0.94%19:19 EDT
Volume:1.10M
Turnover:1.17M
Market Cap:402.61M
PE:-2.99
High:1.10
Open:1.01
Low:1.00
Close:0.9939
Loading ...

KeyBanc Downgrades Standard BioTools to Sector Weight From Overweight, Removes $4 Price Target

MT Newswires Live
·
27 Feb

Standard BioTools Inc. : Keybanc Cuts to Sector Weight From Overweight

THOMSON REUTERS
·
27 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Standard BioTools (LAB) and Ardent Health Partners, Inc. (ARDT)

TIPRANKS
·
27 Feb

Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com
·
27 Feb

Standard BioTools: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

Standard BioTools Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Standard BioTools Q4 EPS $(0.09) Misses $(0.07) Estimate, Sales $46.72M Beat $43.03M Estimate

Benzinga
·
27 Feb

Standard BioTools Inc Outlook Fiscal Year 2025 Revenue in Range of $165 Mln to $175 Mln

THOMSON REUTERS
·
27 Feb

Standard BioTools Q4 Operating Income USD -32.8 Million

THOMSON REUTERS
·
27 Feb

Standard BioTools Q4 Gross Margin 46.9%

THOMSON REUTERS
·
27 Feb

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
27 Feb

Shareholders in Standard BioTools (NASDAQ:LAB) have lost 66%, as stock drops 10.0% this past week

Simply Wall St.
·
26 Feb

EVS reports 2024 results

GlobeNewswire
·
19 Feb

NAVER D2SF Invests in "STUDIO LAB," an AI-Powered E-Commerce Content Generation Startup

PR Newswire
·
15 Feb

CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

PR Newswire
·
30 Jan

Strength Seen in American Well (AMWL): Can Its 18.8% Jump Turn into More Strength?

Zacks
·
14 Jan

Standard BioTools Up 28%, on Pace for Largest Percent Increase Since May 2022 -- Data Talk

Dow Jones
·
14 Jan

BRIEF-Standard Biotools Announces Preliminary Fourth Quarter And Full Year 2024 Revenue

Reuters
·
13 Jan

In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$52m market cap drop, institutional owners may be forced to take severe actions

Simply Wall St.
·
13 Jan

Standard BioTools Announced Preliminary Revenue For Q4 And FY 2024 Of Approximately $46.5M And $174M, Respectively, Compared To Consensus Of $43.03M And $171.20M

Benzinga
·
13 Jan